文献速递发热待查

原因不明发热与癌症发病率

Fever of Unknown Origin and Incidence of Cancer.
PubMed 文献 · Clin Infect Dis · 2022-01-01

基于丹麦全国登记数据的20年人群队列研究显示,6620例原因不明发热(FUO)患者中,1至<12个月癌症标化发病比为2.3(95%CI 1.8-2.9),绝对风险1.2%,此后多数癌症发病率与一般人群相当;1至<12个月癌症标化发病比随时间推移而降低,2013-2017年期间未见超额风险。

要点

  • FUO患者1至<12个月癌症标化发病比为2.3(95%CI 1.8-2.9),绝对风险1.2%。
  • 1至<12个月超额风险主要见于霍奇金淋巴瘤(SIR=41.7)、非霍奇金淋巴瘤(SIR=16.1)、骨髓增生异常综合征/慢性骨髓增殖性疾病(SIR=6.0)、下消化道癌(SIR=3.3)和泌尿道癌(SIR=2.9)。
  • 1至<12个月癌症SIR随时间推移而降低,2013-2017年期间未发现超额风险。

核心结论

  • FUO患者1至<12个月癌症SIR升高,此后多数癌症发病率与一般人群相当。
  • SIR随时间推移而降低,提示FUO初始诊断检查有所改进。

研究设计与样本

  • 基于人群的队列研究,使用丹麦全国登记数据。
  • 识别1998-2017年诊断为FUO的个体,量化其与一般人群相比的癌症超额风险。
  • 癌症随访自FUO诊断后1个月开始,共纳入6620例FUO患者(46.9%为男性;中位年龄39岁)。

主要发现

  • 6620例FUO患者中343例诊断为癌症(中位随访6.5年)。
  • 1至<12个月癌症风险为1.2%,SIR为2.3(95%CI 1.8-2.9)。
  • 1至<12个月SIR升高主要由于霍奇金淋巴瘤(SIR=41.7)、非霍奇金淋巴瘤(SIR=16.1)、骨髓增生异常综合征/慢性骨髓增殖性疾病(SIR=6.0)、下消化道癌(SIR=3.3)和泌尿道癌(SIR=2.9)的超额。
  • 1年随访之后,恶性黑色素瘤、肝胆道/胰腺癌和脑/中枢神经系统/眼癌的诊断频率高于预期。
  • 1至<12个月癌症SIR随时间推移而降低,2013-2017年期间未发现超额风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Diagnostic tools for determining causes of fever of unknown origin (FUO) have improved over time. We examined if cancer incidence among these patients changed over a 20-year period. METHODS: Population-based cohort study using nationwide Danish registries. We identified individuals diagnosed with FUO (1998-2017) to quantify their excess risk of cancer compared with the general population. Follow-up for cancer started 1 month after FUO. We computed absolute risks and standardized incidence ratios (SIRs) of cancer, and mortality rate ratios adjusted for age, sex, and cancer stage. RESULTS: Among 6620 patients with FUO (46.9% male; median age: 39 years), 343 were diagnosed with cancer (median follow-up: 6.5 years). The 1- to <12-month risk was 1.2%, and the SIR was 2.3 (95% CI, 1.8-2.9). The increased 1- to <12-month SIR was mainly due to an excess of Hodgkin lymphoma (SIR = 41.7) non-Hodgkin lymphoma (SIR = 16.1), myelodysplastic syndrome/chronic myeloproliferative diseases (SIR = 6.0), lower gastrointestinal cancer (SIR = 3.3), and urinary tract cancer (SIR = 2.9). Beyond 1-year follow-up, malignant melanoma, hepatobiliary tract/pancreatic cancer, and brain/CNS/eye cancer were diagnosed more often than expected. The 1- to <12-month cancer SIR attenuated over time, and for the 2013-2017 period we found no excess risk. Patients diagnosed with cancer ≤1 year after FUO had similar mortality to cancer patients without this diagnosis. CONCLUSIONS: Patients with FUO have a higher 1- <12-month cancer SIR; thereafter, the incidence for most cancers equals that of the general population. Decreasing SIRs over time suggests improvements in the initial diagnostic workup for FUO.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Søgaard KK, Farkas DK, Leisner MZ, et al. Fever of Unknown Origin and Incidence of Cancer. Clin Infect Dis. 2022. PMID: 35079799. doi:10.1093/cid/ciac040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。